Although first-generation HDACi such as vorinostat, panobinostat, and romidepsin demonstrated encouraging preclinical activity, their broad inhibition of multiple HDAC isoforms has resulted in a characteristic on-target, off-tumor dose-limiting toxicity (DLT) profile in the clinic. Here, HDAC9 is linked to neoplasm.